Top Markets
Coin of the day
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
Rangering i aksjer #39173
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
Aksjekurs
$0.378
Sist synkronisert: 2024-05-24
Markedsverdi
$618.41K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel NeuBase Therapeutics, Inc. (NBSE)

Kategori

Pris NBSE pris med markedsverdi på B
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.
NBSE
$0.378
Markedsverdi av NeuBase Therapeutics, Inc.(NBSE)
Markedsverdi: $618.41K
Per August 2026 har NeuBase Therapeutics, Inc. en markedsverdi på $618.41K. Dette gjør NeuBase Therapeutics, Inc. til det 39173rd mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for NeuBase Therapeutics, Inc. fra 2004 til 2026
NBSE sammenlignet med topp 5 mest populære stocks
Pris på NBSE Eiendel B Markedsverdi for B Resultater
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.
$3,343,238 $618.41K
$5.470T +884,454,463.65%
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.
$2,730,484 $618.41K
$4.467T +722,350,064.17%
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.
$2,551,581 $618.41K
$4.174T +675,021,304.38%
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.
$2,261,661 $618.41K
$3.700T +598,322,901.89%
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.
$1,744,708 $618.41K
$2.854T +461,562,929.50%